11/19
08:20 am
alzn
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice [Yahoo! Finance]
Medium
Report
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer's Transgenic Mice [Yahoo! Finance]
11/19
08:00 am
alzn
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
Low
Report
Alzamend Neuro Announces Full Data Set from its Nonclinical Study: Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimer’s Transgenic Mice
11/19
07:36 am
alzn
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential [Yahoo! Finance]
Medium
Report
EXCLUSIVE: Alzamend Neuro Reveals Full Data From Nonclinical Study Of Its Lead Alzheimer's Drug Potential [Yahoo! Finance]
11/11
08:10 am
alzn
Alzamend Neuro, Inc. (NASDAQ: ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $50.00 to $35.00. They now have a "buy" rating on the stock.
Low
Report
Alzamend Neuro, Inc. (NASDAQ: ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $50.00 to $35.00. They now have a "buy" rating on the stock.
10/16
08:00 am
alzn
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Medium
Report
Alzamend Neuro Announces Full Data Set from Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
10/16
07:35 am
alzn
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's [Yahoo! Finance]
Medium
Report
EXCLUSIVE: Alzamend Neuro Reveals Full Data Set From Multiple Ascending Dose Trial For Lead Candidate For Dementia Related to Alzheimer's [Yahoo! Finance]
10/15
08:15 am
alzn
Alzamend Neuro regains compliance with Nasdaq [Seeking Alpha]
Low
Report
Alzamend Neuro regains compliance with Nasdaq [Seeking Alpha]
10/15
08:00 am
alzn
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
Medium
Report
Alzamend Neuro Regains Compliance with Nasdaq Listing Standards
10/10
08:00 am
alzn
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
Low
Report
Alzamend Neuro CEO Stephan Jackman to Participate in the Maxim Group’s Virtual Healthcare Conference
8/26
08:00 am
alzn
Alzamend Neuro Issues Letter to Stockholders
Medium
Report
Alzamend Neuro Issues Letter to Stockholders